Immediate risk of cervical intraepithelial neoplasia and diagnostic value of colposcopy among cytology-negative women with oncogenic HPV: a retrospective study.
Humans
Female
Colposcopy
/ statistics & numerical data
Retrospective Studies
Uterine Cervical Dysplasia
/ diagnosis
Adult
Papillomavirus Infections
/ diagnosis
Middle Aged
Uterine Cervical Neoplasms
/ diagnosis
Human papillomavirus 18
/ isolation & purification
Human papillomavirus 16
/ isolation & purification
Early Detection of Cancer
/ methods
Young Adult
Cytology
Cervical biopsy
Cervical cancer screening
Cervical dysplasia
Diagnostic value
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
19
02
2024
accepted:
10
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Cervical cancer screening results that are negative for cytology but positive for high-risk human papillomavirus (HR-HPV) are not uncommon. One-year follow-up is suggested for patients with no history of HPV positivity under the most recent American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines (2019). The aim of this study was to evaluate the immediate risk of cervical intraepithelial neoplasia (CIN) among cytology-negative patients positive for HR-HPV. The diagnostic accuracy of colposcopy in these patients was investigated. A retrospective study was conducted in patients who were cytology negative but HR-HPV positive and referred for colposcopy from January 2022 to August 2023. Patients were compared in terms of the immediate rate of CIN lesions among the HPV16-positive group, the HPV18-positive group and the non-16/18 HR-HPV-positive group. The distribution of CIN2 + lesions according to age was evaluated. The factors associated with the accuracy of colposcopy were evaluated using univariate and multivariate logistic regression. Among the 372 patients, 195 had chronic cervicitis, 131 had CIN1, 37 had CIN2/3, and nine had carcinoma. The immediate rates of CIN2 + lesions and CIN3 + lesions in patients who were not HR-HPV16/18-positive were comparable to those in patients who were HPV16/18-positive (P = 0.699). In addition, among patients diagnosed with CIN2 + lesions, 8 (17.39%) patients were women aged < 30 years. When pathological results were used as a reference, the consistency rate of colposcopy was 61.0% (227/372). Multivariate analyses revealed that age and the type of cervical transformation zone were independent factors affecting the accuracy of colposcopy (P < 0.001). In countries with limited resources, immediate colposcopy referral should be recommended for patients who are cytology negative but HR-HPV-positive (including non-16/18 HR-HPV-positive), and cervical cancer screening via cotesting should be suggested for women aged < 30 years. Colposcopy has moderate diagnostic value and can be affected by age and the type of cervical transformation zone.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer screening results that are negative for cytology but positive for high-risk human papillomavirus (HR-HPV) are not uncommon. One-year follow-up is suggested for patients with no history of HPV positivity under the most recent American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines (2019). The aim of this study was to evaluate the immediate risk of cervical intraepithelial neoplasia (CIN) among cytology-negative patients positive for HR-HPV. The diagnostic accuracy of colposcopy in these patients was investigated.
METHODS
METHODS
A retrospective study was conducted in patients who were cytology negative but HR-HPV positive and referred for colposcopy from January 2022 to August 2023. Patients were compared in terms of the immediate rate of CIN lesions among the HPV16-positive group, the HPV18-positive group and the non-16/18 HR-HPV-positive group. The distribution of CIN2 + lesions according to age was evaluated. The factors associated with the accuracy of colposcopy were evaluated using univariate and multivariate logistic regression.
RESULTS
RESULTS
Among the 372 patients, 195 had chronic cervicitis, 131 had CIN1, 37 had CIN2/3, and nine had carcinoma. The immediate rates of CIN2 + lesions and CIN3 + lesions in patients who were not HR-HPV16/18-positive were comparable to those in patients who were HPV16/18-positive (P = 0.699). In addition, among patients diagnosed with CIN2 + lesions, 8 (17.39%) patients were women aged < 30 years. When pathological results were used as a reference, the consistency rate of colposcopy was 61.0% (227/372). Multivariate analyses revealed that age and the type of cervical transformation zone were independent factors affecting the accuracy of colposcopy (P < 0.001).
CONCLUSIONS
CONCLUSIONS
In countries with limited resources, immediate colposcopy referral should be recommended for patients who are cytology negative but HR-HPV-positive (including non-16/18 HR-HPV-positive), and cervical cancer screening via cotesting should be suggested for women aged < 30 years. Colposcopy has moderate diagnostic value and can be affected by age and the type of cervical transformation zone.
Identifiants
pubmed: 39049047
doi: 10.1186/s12905-024-03258-x
pii: 10.1186/s12905-024-03258-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419Subventions
Organisme : Startup Fund for scientific research, Fujian Medical University
ID : 2019QH1058
Organisme : Startup Fund for scientific research, Fujian Medical University
ID : 2019QH1025
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
Golia D’Augè, Cuccu T, Etrusco I, D’Amato A, Laganà A, D’Oria AS. State of the art on HPV-related cervical lesions. Ital J Gynaecol Obstet. 2024;135–7. https://doi.org/10.36129/jog.2024.161 .
Wang SM, Qiao YL. Implementation of cervical cancer screening and prevention in China–challenges and reality. Jpn J Clin Oncol. 2015;45(1):7–11. https://doi.org/10.1093/jjco/hyu188 .
doi: 10.1093/jjco/hyu188
pubmed: 25398583
Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–88. https://doi.org/10.1093/jnci/djq356 .
doi: 10.1093/jnci/djq356
pubmed: 20841605
pmcid: 2950170
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet (London England). 2013;382(9895):889–99. https://doi.org/10.1016/s0140-6736(13)60022-7 .
doi: 10.1016/s0140-6736(13)60022-7
pubmed: 23618600
Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet. 2005;89(Suppl 2):S4–12. https://doi.org/10.1016/j.ijgo.2005.01.009 .
doi: 10.1016/j.ijgo.2005.01.009
pubmed: 15823266
Chadha S, Gandhi G, Hedau ST, Gupta R. Comparison of HPV 16/18 genotyping and p16/Ki67 dual staining for detection of high-Grade cervical lesion in patients with low-Grade Cervical smears. J Obstet Gynecol India. 2015;73(3):248–53. https://doi.org/10.1007/s13224-022-01731-x .
doi: 10.1007/s13224-022-01731-x
Torres-Poveda K, Ruiz-Fraga I, Madrid-Marina V, Chavez M, Richardson V. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program. BMC Cancer. 2019;19(1):1205. https://doi.org/10.1186/s12885-019-6388-4 .
doi: 10.1186/s12885-019-6388-4
pubmed: 31823749
pmcid: 6905062
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (London England). 2014;383(9916):524–32. https://doi.org/10.1016/s0140-6736(13)62218-7 .
doi: 10.1016/s0140-6736(13)62218-7
pubmed: 24192252
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Lower Genit Tract Dis. 2012;16(3):175–204. https://doi.org/10.1097/LGT.0b013e31824ca9d5 .
doi: 10.1097/LGT.0b013e31824ca9d5
Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–59. https://doi.org/10.1002/ijc.27485 .
doi: 10.1002/ijc.27485
pubmed: 22323075
Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. https://doi.org/10.1016/j.eclinm.2020.100293 .
doi: 10.1016/j.eclinm.2020.100293
pubmed: 32510043
pmcid: 7264956
Gu L, Hong Z, Gao H, Qiu L, Di W. Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: a retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype. Cytopathol. 2019;30(4):419–25. https://doi.org/10.1111/cyt.12717 .
doi: 10.1111/cyt.12717
Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol. 2001;195(3):300–6. https://doi.org/10.1002/path.981 .
doi: 10.1002/path.981
pubmed: 11673826
Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 3 + and cervical cancer among women who test pap-negative but are HPV-positive. J Lower Genit Tract Dis. 2013;17(5 Suppl 1):S56–63. https://doi.org/10.1097/LGT.0b013e318285437b .
doi: 10.1097/LGT.0b013e318285437b
Kurtycz DFI, Staats PN, Chute DJ, Russell D, Pavelec D, Monaco SE, et al. Bethesda Interobserver Reproducibility Study-2 (BIRST-2): Bethesda System 2014. J Am Soc Cytopathol. 2017;6(4):131–44. https://doi.org/10.1016/j.jasc.2017.03.003 .
doi: 10.1016/j.jasc.2017.03.003
pubmed: 31043266
Bornstein J, Bentley J, Bösze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2012;120(1):166–72. https://doi.org/10.1097/AOG.0b013e318254f90c .
doi: 10.1097/AOG.0b013e318254f90c
pubmed: 22914406
Wang M, Kartsonaki C, Guo Y, Lv J, Gan W, Chen ZM, et al. Factors related to age at natural menopause in China: results from the China Kadoorie Biobank. Menopause (New York NY). 2021;28(10):1130–42. https://doi.org/10.1097/gme.0000000000001829 .
doi: 10.1097/gme.0000000000001829
Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ (Clinical Researched). 2016;355:i4924. https://doi.org/10.1136/bmj.i4924 .
doi: 10.1136/bmj.i4924
Petousis S, Christidis P, Margioula-Siarkou C, Sparangis N, Athanasiadis A, Kalogiannidis I. Discrepancy between colposcopy, punch biopsy and final histology of cone specimen: a prospective study. Arch Gynecol Obstet. 2018;297(5):1271–5. https://doi.org/10.1007/s00404-018-4714-8 .
doi: 10.1007/s00404-018-4714-8
pubmed: 29442140
Malagón T, Volesky KD, Bouten S, Laprise C, El-Zein M, Franco EL. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: systematic review and meta-analysis. Int J Cancer. 2020;147(10):2695–707. https://doi.org/10.1002/ijc.33035 .
doi: 10.1002/ijc.33035
pubmed: 32363604
Song F, Yan P, Huang X, Wang C, Qu X, Du H, et al. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16(INK4a) immunostaining in China. BMC Infect Dis. 2021;21(1):400. https://doi.org/10.1186/s12879-021-06109-4 .
doi: 10.1186/s12879-021-06109-4
pubmed: 33931022
pmcid: 8086315
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors. J Lower Genit Tract Dis. 2020;24(2):102–31. https://doi.org/10.1097/lgt.0000000000000525 .
doi: 10.1097/lgt.0000000000000525
Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk estimates supporting the 2019 ASCCP risk-based Management Consensus guidelines. J Lower Genit Tract Dis. 2020;24(2):132–43. https://doi.org/10.1097/lgt.0000000000000529 .
doi: 10.1097/lgt.0000000000000529
Yarandi F, Shirali E, Feizabad E, Ramhormoziyan S, Sarmadi S, SadrAmeli M, et al. Cervical intraepithelial neoplasia in non-16/18 high-risk human papilloma virus positive/cytology negative women: an alternative approach in poor resource areas. Taiwan J Obstet Gynecol. 2023;62(2):299–303.
doi: 10.1016/j.tjog.2022.12.003
pubmed: 36965899
Kabaca C, Giray B, Guray Uzun M, Akis S, Purut YE, Keles Peker E, et al. The meaning of high-risk HPV other than type 16/18 in women with negative cytology: is it really safe to wait for 1 year? Diagn Cytopathol. 2021;49(4):480–6.
doi: 10.1002/dc.24705
pubmed: 33528903
Karaca İ, Öztürk M, Comba C, Demirayak G, Alay İ, Erdoğan V, et al. Immediate biopsy of cervical cytology-negative and non-HPV-16/18 oncogenic types positive patients. Diagn Cytopathol. 2018;46(4):326–30. https://doi.org/10.1002/dc.23905 .
doi: 10.1002/dc.23905
pubmed: 29460502
Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, Athena HPV, Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):e1841–11. https://doi.org/10.1016/j.ajog.2012.11.020 .
doi: 10.1016/j.ajog.2012.11.020
Wang S, Li L, Yang J, Han N, Bao H, Wang HJ. Comparison of different HPV-based strategies and Cytology in Routine Cervical Cancer Screening Programme in China: a Population-based study. Cancer Prev Res (Phila). 2022;15(1):45–54. https://doi.org/10.1158/1940-6207.CAPR-21-0104 .
doi: 10.1158/1940-6207.CAPR-21-0104
pubmed: 34556493
Zappacosta R, Lattanzio G, Viola P, Ianieri MM, Gatta DM, Rosini S. A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative pap cytology. Clin Interv Aging. 2014;9:683–8. https://doi.org/10.2147/CIA.S57294 .
doi: 10.2147/CIA.S57294
pubmed: 24790420
pmcid: 3998847
Bai A, Xue P, Li Q, Jiang Y, Qiao Y. Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: a multicenter retrospective study. Cancer Med. 2023;12(13):14794–805. https://doi.org/10.1002/cam4.6109 .
doi: 10.1002/cam4.6109
pubmed: 37199394
pmcid: 10358197
Zhang J, Zhang D, Yang Z, Wang X, Wang D. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China. BMC Cancer. 2020;20(1):443. https://doi.org/10.1186/s12885-020-06935-w .
doi: 10.1186/s12885-020-06935-w
pubmed: 32429919
pmcid: 7236298
Patel A, Galaal K, Burnley C, Faulkner K, Martin-Hirsch P, Bland MJ, et al. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. Br J Cancer. 2012;106(11):1753–9. https://doi.org/10.1038/bjc.2012.148 .
doi: 10.1038/bjc.2012.148
pubmed: 22531636
pmcid: 3364121
Gumpeny N, Devi A. Pattern of cervical lesions, with emphasis on precancer and cancer in a tertiary care hospital of Southern India. Int J Res Med Sci. 2015;3:1122–4.
doi: 10.5455/2320-6012.ijrms20150517
Tidy JA, Lyon R, Ellis K, Macdonald M, Palmer JE. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study. BJOG. 2020;127(10):1260–7. https://doi.org/10.1111/1471-0528.16250 .
doi: 10.1111/1471-0528.16250
pubmed: 32279427
Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8(1):6383. https://doi.org/10.1038/s41598-018-24882-2 .
doi: 10.1038/s41598-018-24882-2
pubmed: 29686397
pmcid: 5913272
Sykes PH, Simcock BJ, Innes CR, Harker D, Williman JA, Whitehead M, et al. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. Am J Obstet Gynecol. 2022;226(2):222. .e1-222.e13.
doi: 10.1016/j.ajog.2021.09.009
Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Giannini A, et al. Italian society of Colposcopy and Cervico-Vaginal Pathology (SICPCV); the investigators of the Italian HPV study group (iHPV study group). Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023;32(6):525–32. https://doi.org/10.1097/CEJ.0000000000000822 .
doi: 10.1097/CEJ.0000000000000822
pubmed: 37401466
Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Ghezzi F, et al. HPV persistence after cervical surgical excision of high-grade cervical lesions. Cancer Cytopathol. 2024;132(5):268–9. https://doi.org/10.1002/cncy.22760 .
doi: 10.1002/cncy.22760
pubmed: 37747763
Chelmow D. Practice Bulletin 168: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;128(4):e111.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674–86. https://doi.org/10.1001/jama.2018.10897 .
doi: 10.1001/jama.2018.10897
pubmed: 30140884
Liu Y, Liao J, Yi X, Pan Z, Pan J, Sun C, et al. Diagnostic value of colposcopy in patients with cytology-negative and HR-HPV-positive cervical lesions. Arch Gynecol Obstet. 2022;306(4):1161–9.
doi: 10.1007/s00404-022-06415-5
pubmed: 35320389
Wei B, Zhang B, Xue P, Seery S, Wang J, Li Q, et al. Improving colposcopic accuracy for cervical precancer detection: a retrospective multicenter study in China. BMC Cancer. 2022;22(1):388.
doi: 10.1186/s12885-022-09498-0
pubmed: 35399061
pmcid: 8994905
Bai A, Wang J, Li Q, Seery S, Xue P, Jiang Y. Assessing colposcopic accuracy for high-grade squamous intraepithelial lesion detection: a retrospective, cohort study. BMC Womens Health. 2022;22(1):9. https://doi.org/10.1186/s12905-022-01592-6 .
doi: 10.1186/s12905-022-01592-6
pubmed: 35012523
pmcid: 8751223
Karimi-Zarchi M, Peighmbari F, Karimi N, Rohi M, Chiti Z. A comparison of 3 Ways of Conventional Pap Smear, Liquid-based cytology and colposcopy vs cervical biopsy for early diagnosis of Premalignant lesions or Cervical Cancer in women with abnormal conventional pap test. Int J Biomedical Science: IJBS. 2013;9(4):205–10.
doi: 10.59566/IJBS.2013.9205
Qin D, Bai A, Xue P, Seery S, Wang J, Mendez MJG, et al. Colposcopic accuracy in diagnosing squamous intraepithelial lesions: a systematic review and meta-analysis of the International Federation of Cervical Pathology and Colposcopy 2011 terminology. BMC Cancer. 2023;23(1):187. https://doi.org/10.1186/s12885-023-10648-1 .
doi: 10.1186/s12885-023-10648-1
pubmed: 36823557
pmcid: 9951444
Liu Y, Liao J, Yi X, Pan Z, Pan J, Sun C, et al. Diagnostic value of colposcopy in patients with cytology-negative and HR-HPV-positive cervical lesions. Arch Gynecol Obstet. 2022;306(4):1161–9. https://doi.org/10.1007/s00404-022-06415-5 .
doi: 10.1007/s00404-022-06415-5
pubmed: 35320389
Ara R, Khatun S, Pervin S, Jahan M, Shahera U, Ferdous J, et al. Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. Gynecol Oncol. 2020;158(3):590–6. https://doi.org/10.1016/j.ygyno.2020.06.496 .
doi: 10.1016/j.ygyno.2020.06.496
pubmed: 32680634